148 related articles for article (PubMed ID: 17229652)
1. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias.
Illmer T; Schaich M; Ehninger G; Thiede C;
Haematologica; 2007 Jan; 92(1):137-8. PubMed ID: 17229652
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].
Li WY; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):797-801. PubMed ID: 19176031
[TBL] [Abstract][Full Text] [Related]
5. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
7. Morphologic and Molecular Characteristics of De Novo AML With
Hidalgo-López JE; Kanagal-Shamanna R; Medeiros LJ; Estrov Z; Yin CC; Verstovsek S; Konoplev S; Jorgensen JL; Mohammad MM; Miranda RN; Zhao C; Lee J; Zuo Z; Bueso-Ramos CE
J Natl Compr Canc Netw; 2017 Jun; 15(6):790-796. PubMed ID: 28596259
[No Abstract] [Full Text] [Related]
8. Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.
Ding W; Li D; Zhuang C; Wei P; Mou W; Zhang L; Liang H; Liu Y
Medicine (Baltimore); 2018 Jul; 97(27):e11331. PubMed ID: 29979407
[TBL] [Abstract][Full Text] [Related]
9. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.
Bullinger L; Rücker FG; Kurz S; Du J; Scholl C; Sander S; Corbacioglu A; Lottaz C; Krauter J; Fröhling S; Ganser A; Schlenk RF; Döhner K; Pollack JR; Döhner H
Blood; 2007 Aug; 110(4):1291-300. PubMed ID: 17485551
[TBL] [Abstract][Full Text] [Related]
10. Screening of V617F mutation in JAK2 gene with acute myeloid leukemia in the Saudi population.
Farasani A
Acta Biochim Pol; 2022 Feb; 69(1):211-214. PubMed ID: 35189054
[TBL] [Abstract][Full Text] [Related]
11. Leukemic transformation in essential thrombocythemia.
Bhatt VR
Future Oncol; 2014 Dec; 10(16):2593-602. PubMed ID: 25531047
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
Tan Y; Liu Z; Wang W; Zhu G; Guo J; Chen X; Zheng C; Xu Z; Chang J; Ren F; Wang H
Leuk Res; 2018 Jun; 69():89-93. PubMed ID: 29705537
[TBL] [Abstract][Full Text] [Related]
13. The JAK2 V617F mutation in de novo acute myelogenous leukemias.
Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; Rhim HS; Min WS; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
Oncogene; 2006 Mar; 25(9):1434-6. PubMed ID: 16247455
[TBL] [Abstract][Full Text] [Related]
14. Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient.
Hsiao HH; Yang WC; Liu YC; Lee CP; Lin SF
Leuk Res; 2008 Aug; 32(8):1323-4. PubMed ID: 18078991
[No Abstract] [Full Text] [Related]
15. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
16. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract][Full Text] [Related]
17. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L
Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268
[TBL] [Abstract][Full Text] [Related]
18. [Genetic abnormalities in core binding factor acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
Ohanian M; Bueso-Ramos C; Ok CY; Lin P; Patel K; Alattar ML; Khoury JD; Rozovski U; Estrov Z; Huh YO; Cortes J; Abruzzo LV
Cancer Genet; 2015 Nov; 208(11):571-4. PubMed ID: 26382622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]